# Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics

Study · id `cardio:ct-nct06948292` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06948292](<https://clinicaltrials.gov/study/NCT06948292>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06948292

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 127 participants.

## Technical summary

Registry record NCT06948292. Non-randomized; double masking; primary purpose treatment. Start 2023-03-01 (actual); primary completion 2024-08-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 127 participants (enrolled count; ClinicalTrials.gov record NCT06948292, source copy `cardio:ctgov-nct06948292-2025-09-08`, retrieved 2026-10-26)
- Started: 2023-03-01 (actual) (ClinicalTrials.gov record NCT06948292, source copy `cardio:ctgov-nct06948292-2025-09-08`, retrieved 2026-10-26)
- Primary completion: 2024-08-30 (actual) (ClinicalTrials.gov record NCT06948292, source copy `cardio:ctgov-nct06948292-2025-09-08`, retrieved 2026-10-26)
- Completion: 2024-10-30 (actual) (ClinicalTrials.gov record NCT06948292, source copy `cardio:ctgov-nct06948292-2025-09-08`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06948292, source copy `cardio:ctgov-nct06948292-2025-09-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06948292-2025-09-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics
- Acronym: QRX-3 in CKD
- Condition: Chronic Kidney Disease Stages 3-5
- Condition: Diabetic Kidney Disease
- Condition: Hypertensive Kidney Disease
- Intervention (Drug): QRX-3
- Lead sponsor: Ebima Clifford Okundaye
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 85f1d52089eeb1fd53a1c7830f2c1cc7fc3cfc5ff546534c30369f4c72e548f8
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
